Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00540007 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00540007 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 80 participants.
The verdict
NCT00540007, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of lenalidomide in the treatment of relapsed or refractory classic Hodgkin lymphoma(cHL).
Interventions
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2007-09-06 |
| Est. Completion | 2016-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00540007
The ClinicalTrials.gov registry entry for NCT00540007 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide is the first listed.
NCT00540007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00540007 about?
NCT00540007 is a clinical study titled "Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma". The purpose of this study is to determine the efficacy of lenalidomide in the treatment of relapsed or refractory classic Hodgkin lymphoma(cHL).
What is the current status of trial NCT00540007?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2007-09-06. Estimated completion is 2016-09-01.
What interventions are being tested in trial NCT00540007?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00540007?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.